The petitioner has sought the supervision of such a study by a retired SC judge. Further, the plea seeks directions to the Central government to establish a ‘vaccine damage payment system’ for citizens “who got severely disabled as a result of a vaccination Drive during Covid 19.”
In addition, the plea seeks compensation of people who were severely disabled or died because of the side effects of Corona vaccine administered to them during the Covid-19 pandemic.
ALSO READ: Bereaved parents to take Serum Institute of India to Court following AstraZeneca’s rare side effect admission
Covishield controversy
Controversy erupted when UK-based pharmaceutical giant AstraZeneca admitted that its Covid vaccine could cause blood clot-related side effects ‘in very rare cases’.
The Daily Telegraph reported that AstraZeneca in a legal document submitted to the London High Court said that the vaccine, which was developed with the University of Oxford, could cause Thrombosis with Thrombocytopenia Syndrome (TTS) in “very rare cases”.
The very same vaccine was manufactured by the Serum Institute of India (SII) and was known in India as Covishield.
ET earlier reported that parents of woman who allegedly passed away after taking the Covishield vaccine decided to take legal action against SII.
“It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known. Further, TTS can also occur in the absence of the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence,” the newspaper quotes the legal document as stating.
ALSO READ: What’s TTS syndrome, symptoms, and danger signs you shouldn’t ignore
Reacting to the reports, AstraZeneca said that its sympathies goes out to anyone who has lost their loved ones.
“Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority, and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines,” AstraZeneca said in a statement.
“From the body of evidence in clinical trials and real-world data, the AstraZeneca-Oxford vaccine has continuously been shown to have an acceptable safety profile and regulators around the world consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects,” it noted.
